logo
logo

Casma Therapeutics Announces $50 Million Series B Financing

Casma Therapeutics Announces $50 Million Series B Financing

09/10/20, 4:08 AM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svgcambridge
Money raised
$50 million
Round Type
series b
Casma Therapeutics, Inc., a biotechnology company harnessing autophagy and the lysosome to design powerful new medicines, today announced the completion of a $50 million Series B financing.

Company Info

Company
Casma Therapeutics
Location
cambridge, maryland, united states
Additional Info
Casma Therapeutics is harnessing the natural cellular process of autophagy to open vast new target areas for drug discovery and development. Casma uses several approaches to intervene at strategic points in the autophagy-lysosome system to improve the cellular process of enhancing membrane repair and clearing out unwanted proteins, aggregates, organelles and invading pathogens. By boosting autophagy, Casma expects to be able to arrest or reverse the progression of lysosomal storage disorders, muscle disorders, cancer, inflammatory disorders and neurodegeneration, among other indications. Casma was launched in 2018 by Third Rock Ventures and is based in Cambridge, Mass. For more information, please visit www.casmatx.com.

Related People